New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
07:04 EDTTRVNTrevena initiates TRV734 clinical development
Trevena announced the initiation of its first Phase 1 trial for TRV734. TRV734 is being developed to optimize analgesia while minimizing on-target gastrointestinal and respiratory effects through its novel biased ligand mechanism at the mu-opioid receptor. TRV734 takes advantage of the same receptor specificity mechanism as does Trevena’s Phase 2 clinical candidate, TRV130. The main objective of this first-in-human trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of TRV734 in healthy subjects. The potentially efficacious dose range of TRV734 will also be evaluated using pupilometry, a validated biomarker for mu-opioid receptor engagement.
News For TRVN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2015
16:03 EDTTRVNTrevena announces publication of Phase 2a/b data on TRV130
Trevena announced the publication of the full results from its Phase 2a/b trial of TRV130 in postoperative pain following bunionectomy surgery in the online edition of PAIN, the Journal of the International Association for the Study of Pain. Chief Medical Mfficer David Soergel commented, "This study provided us with important insights on the potential differentiation of TRV130 from morphine in a fixed dose setting, paving the way for the positive results from our recent Phase 2b trial of the candidate following abdominoplasty surgery. The abdominoplasty study utilized more clinically relevant on-demand dosing and showed better safety and tolerability for TRV130 than morphine with comparable levels of pain relief."
September 25, 2015
09:23 EDTTRVNCowen pharmaceutical analysts to hold an analyst/industry conference call
Analysts, along with Dr. Lynn Webster, discuss Trevena's TRV-130, a small molecule biased ligand at the mu-opioid receptor that the company is developing as a first-line intravenous treatment for moderate-to-severe acute pain, on an Analyst/Industry conference call to be held on September 25 at 10 am.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use